You need to create a user account to read this article.
With a subscription you unlock more content on BioStock.
Xbrane on the FDA drama: "We are taking it seriously" while outlining the path forward
Text:
Hanna Norrlid | [email protected]
After the FDA's unexpected setback for the biosimilar Ximluci, Xbrane's stock plunged by over 35 percent last week. Now the company has released its Q3 report and answered investors' questions in detail in...